These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group. Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559 [TBL] [Abstract][Full Text] [Related]
23. Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature. Sentongo TA; Piccoli DA J Pediatr Gastroenterol Nutr; 1998 Sep; 27(3):344-7. PubMed ID: 9740210 [No Abstract] [Full Text] [Related]
25. [Ulcerative colitis. When is standard therapy enough?]. Stange EF MMW Fortschr Med; 2000 Oct; 142(41):39-40. PubMed ID: 11085075 [No Abstract] [Full Text] [Related]
26. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857 [TBL] [Abstract][Full Text] [Related]
27. Severe skeletal muscle damage following the administration of mesalazine to a patient with ulcerative colitis. Tabata N; Sugimoto K; Ueda S; Sakata N; Okada M; Miyake T; Shinohara T; Yagi M; Satou T; Takemura T Pediatr Int; 2009 Oct; 51(5):759-60. PubMed ID: 19664011 [No Abstract] [Full Text] [Related]
28. [S3 guideline by the German Society of Digestive and Metabolic Diseases and the Competence Network of Chronic Inflammatory Bowel diseases on diagnosis and therapy of ulcerative colitis. An update]. Hoffmann JC; Zeitz M; Med Klin (Munich); 2005 Jan; 100(1):43-50. PubMed ID: 15654542 [No Abstract] [Full Text] [Related]
29. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Harris MS; Lichtenstein GR Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194 [TBL] [Abstract][Full Text] [Related]
30. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Riley SA Gut; 1998 Jun; 42(6):761-3. PubMed ID: 9691909 [No Abstract] [Full Text] [Related]
31. [Thrombopenia in treatment with mesalazine]. Seror P Presse Med; 2000 Sep; 29(27):1510-1. PubMed ID: 11045119 [No Abstract] [Full Text] [Related]
32. [Newcomer in ulcerative colitis: beclomethasone dipropionate: a corticoid with aim: colonic mucosa and colitis]. MMW Fortschr Med; 2004 Jun; 146(23):63. PubMed ID: 15373139 [No Abstract] [Full Text] [Related]
34. ACUTE MYOPERICARDITIS IN A PATIENT WITH ULCERATIVE COLITIS AND THE ROLE OF MESALAMINE: A CASE REPORT. Papaefthymiou A; Kyriakos N; Giakoumis M; Doulberis M; Mylonas I; Kountouras J; Liatsos C Gastroenterol Nurs; 2022 Jul-Aug 01; 45(4):276-277. PubMed ID: 35283437 [No Abstract] [Full Text] [Related]
35. Acute pancreatitis secondary to long-term 5- aminosalicylic acid therapy in a patient with ulcerative colitis: a case-report. Ouakaa-Kchaou A; Gargouri D; Kochlef A; Bibani N; Elloumi H; Trad D; Kharrat J Tunis Med; 2014 Jun; 92(6):423. PubMed ID: 25741849 [No Abstract] [Full Text] [Related]
36. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519 [TBL] [Abstract][Full Text] [Related]
37. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903 [TBL] [Abstract][Full Text] [Related]
38. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V; Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738 [TBL] [Abstract][Full Text] [Related]
39. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. Raedler A; Behrens C; Bias P Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398 [TBL] [Abstract][Full Text] [Related]